Search for Clinical Trial Results

Sponsored By

Lymphoma, T-Cell, Cutaneous - 25 Studies Found

Status Study
Completed Study Name: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Condition: Lymphoma, T-Cell, Cutaneous
Date: 2011-09-09
Interventions:
  • Drug: placebo for SHAPE (SHP-141)

Completed Study Name: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Condition: Lymphoma, T-Cell, Cutaneous
Date: 2011-11-29
Interventions: Drug: Quisinostat, 12 mg Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1
Completed Study Name: CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
Condition: Lymphoma, T-Cell, Cutaneous
Date: 2002-08-08
Interventions:
  • Drug: PF-3512676 Weekly subcut
Completed Study Name: Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Condition: Lymphoma, T-Cell, Cutaneous
Date: 2005-09-13
Interventions: Drug: ONTAK (denileukin difitox, DAB389IL-2)
No longer available Study Name: Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)
Condition: Lymphoma, T-Cell, Cutaneous
Date: 2007-01-05
Interventions: Drug: Comparator: vorinostat Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treat
No longer available Study Name: Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
Condition: Cutaneous T Cell Lymphoma
Date: 2010-05-25
Interventions: Drug: Lenalidomide Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated
Recruiting Study Name: Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
Condition: Cutaneous T Cell Lymphoma
Date: 2014-07-10
Interventions: Drug: Micro needle array-Doxorubicin (MNA-D) MNA-D patches will be applied to 3-4 CTCL skin patches or p
Completed Study Name: Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Date: 2007-01-22
Interventions: Drug: Panobinostat Other Name: LBH589
Withdrawn Study Name: Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
Condition: Cutaneous T-cell Lymphoma
Date: 2009-08-27
Interventions:
  • Drug: Curcumin (Turmeric)

Completed Study Name: A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Date: 2007-02-05
Interventions: Drug: APO866 APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 we
Next >>>